Literature DB >> 12149112

New insights into the relationship between airway inflammation and asthma.

A J Wardlaw1, C E Brightling, R Green, G Woltmann, P Bradding, I D Pavord.   

Abstract

Asthma is a condition characterized by variable airflow obstruction, airway hyper-responsiveness (AHR) and airway inflammation which is usually, but not invariably, eosinophilic. Current thoughts on the pathogenesis of asthma are focused on the idea that it is caused by an inappropriate response of the specific immune system to harmless antigens, particularly allergens such as cat dander and house dust mite, that result in Th2-mediated chronic inflammation. However, the relationship between inflammation and asthma is complex, with no good correlation between the severity of inflammation, at least as measured by the number of eosinophils, and the severity of asthma. In addition, there are a number of conditions, such as eosinophilic bronchitis and allergic rhinitis, in which there is a Th2-mediated inflammatory response, but no asthma, as measured by variable airflow obstruction or AHR. Bronchoconstriction can also occur without obvious airway inflammation, and neutrophilic inflammation can in some cases be associated with asthma. When we compared the immunopathology of eosinophilic bronchitis and asthma, the only difference we observed was that, in asthma, the airway smooth muscle (ASM) was infiltrated by mast cells, suggesting that airway obstruction and AHR are due to an ASM mast cell myositis. This observation emphasizes that the features that characterize asthma, as opposed to bronchitis, are due to abnormalities in smooth muscle responsiveness, which could be intrinsic or acquired, and that inflammation is only relevant in that it leads to these abnormalities. It also emphasizes the importance of micro-localization as an organizing principle in physiological responses to airway inflammation. Thus, if inflammation is localized to the epithelium and lamina propria, then the symptoms of bronchitis (cough and mucus hypersecretion) result, and it is only if the ASM is involved -- for reasons that remain to be established -- that asthma occurs.

Entities:  

Mesh:

Year:  2002        PMID: 12149112     DOI: 10.1042/cs1030201

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  34 in total

Review 1.  Cytokine and anti-cytokine therapy in asthma: ready for the clinic?

Authors:  D Desai; C Brightling
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

2.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

Review 3.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

4.  Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.

Authors:  Melissa J Lathrop; Elice M Brooks; Nick R Bonenfant; Dino Sokocevic; Zachary D Borg; Meagan Goodwin; Roberto Loi; Fernanda Cruz; Chad W Dunaway; Chad Steele; Daniel J Weiss
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

5.  Expression of CCR8 is increased in asthma.

Authors:  K Mutalithas; C Guillen; C Raport; R Kolbeck; D Soler; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  2010-04-28       Impact factor: 5.018

6.  The airway smooth muscle CCR3/CCL11 axis is inhibited by mast cells.

Authors:  R Saunders; A Sutcliffe; L Woodman; D Kaur; S Siddiqui; Y Okayama; A Wardlaw; P Bradding; C Brightling
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

7.  Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6.

Authors:  Fay Hollins; Davinder Kaur; Weidong Yang; Glenn Cruse; Ruth Saunders; Amanda Sutcliffe; Patrick Berger; Akihiko Ito; Christopher E Brightling; Peter Bradding
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

8.  Airway smooth muscle chemokine receptor expression and function in asthma.

Authors:  R Saunders; A Sutcliffe; D Kaur; S Siddiqui; F Hollins; A Wardlaw; P Bradding; C Brightling
Journal:  Clin Exp Allergy       Date:  2009-09-07       Impact factor: 5.018

9.  Airway smooth muscle proliferation and survival is not modulated by mast cells.

Authors:  D Kaur; F Hollins; R Saunders; L Woodman; A Sutcliffe; G Cruse; P Bradding; C Brightling
Journal:  Clin Exp Allergy       Date:  2009-12-16       Impact factor: 5.018

10.  IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis.

Authors:  Salman Siddiqui; Glenn Cruse; Susan McKenna; William Monteiro; Vijay Mistry; Andrew Wardlaw; Christopher Brightling
Journal:  BMC Pulm Med       Date:  2009-07-14       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.